Macitentan in inoperAble or persistent/reCurrent chronIc ThromboEmbolic Pulmonary Hypertension (MACiTEPH)

Purpose of Study:

To evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).

Study Dates:
July 7, 2020 - May 14, 2024

Type of Study:

Study Design:
Controlled Design

Study Location:

Funding Source:
Actelion Pharmaceuticals Ltd*


Janssen Pharmaceutical Company of Johnson & Johnson Identifier:

Register for Trial
Clinical Trials: Why It's Important to Participate
, | Dec 14, 2023